Sulfanizolone | 79028-51-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Sulfanizolone
• 英文别名: N-(4-aminophenyl)sulfonylacetamide;(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
• CAS: 79028-51-6
• 化学式: C29H38N2O8S
• 分子量: 574.7
• InChiKey: OMDDHTUXQGALKO-WDCKKOMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.65
• 重原子数：
  40
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  193
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS
  申请人：Tramonte Arturo

  公开号：US20110240504A1

  公开（公告）日：2011-10-06

  A method of packaging one or more pharmaceuticals comprising separating a plurality of unit doses into a plurality of unit dose compartments, wherein each unit dose compartment of the plurality of unit dose compartments holds only one unit dose of the plurality of unit doses, each unit dose having the same strength, wherein the plurality of unit doses is precisely a quantity equal to a most commonly prescribed number of unit doses in individual prescriptions for the unit dose, or a multiple thereof is provided. Also provided are kits prepared by the method. Methods for designing such kits and packaging are also provided.
• [EN] FIXED DOSE COMBINATION CONTAINING AZITHROMYCIN AND LOTEPREDNOL FOR TREATMENT OF OCULAR INFECTIONS<br/>[FR] COMBINAISON DE DOSE FIXE CONTENANT DE L'AZITHROMYCINE ET DU LOTÉPREDNOL POUR LE TRAITEMENT D'INFECTIONS OCULAIRES
  申请人：MICRO LABS LTD

  公开号：WO2013065028A1

  公开（公告）日：2013-05-10

  The present invention relates to use of a fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections. The present invention further relates to a pharmaceutical composition comprising fixed dose combination comprising an effective amount of Azithromycin or its pharmaceutically acceptable hydrates or salts thereof and an effective amount of Loteprednol or its pharmaceutically acceptable esters or salts thereof for the treatment of ocular infections.
• [EN] COMBINATIONS OF LOTEPREDNOL AND OLOPATADINE FOR THE TREATMENT OF OCULAR ALLERGIES<br/>[FR] ASSOCIATIONS DE LOTEPREDNOL ET D'OLOPATADINE DESTINÉES AU TRAITEMENT DE L'ALLERGIE OCULAIRE
  申请人：MICRO LABS LTD

  公开号：WO2013061269A1

  公开（公告）日：2013-05-02

  The present invention relates to use of a fixed dose combination comprising Loteprednol or its pharmaceutically acceptable esters/salts thereof and Olopatadine or its pharmaceutically acceptable salts thereof for the treatment of ocular allergy. The present invention further relates to a pharmaceutical composition comprising a fixed dose combination comprising Loteprednol or its pharmaceutically acceptable esters/salts thereof and Olopatadine or its pharmaceutically acceptable salts thereof for the treatment of ocular allergy.
• [EN] DOSE COMBINATION COMPRISING NSAID AND STEROIDAL ANTI-INFLAMMATORY AGENT FOR TREATING POST OPERATIVE OCULAR INFLAMMATION<br/>[FR] COMBINAISON DE DOSES COMPRENANT UN AINS ET UN AGENT ANTI-INFLAMMATOIRE STÉROÏDIEN POUR LE TRAITEMENT D'UNE INFLAMMATION OCULAIRE POST-OPÉRATOIRE
  申请人：MICRO LABS LTD

  公开号：WO2013179253A1

  公开（公告）日：2013-12-05

  The present invention relates to use of fixed dose combination comprising Ketorolac or its pharmaceutically acceptable salts thereof and Difluprednate for the treatment of post operative ocular inflammation. The present invention further relates to a pharmaceutical composition comprising fixed dose combination comprising Ketorolac or its pharmaceutically acceptable salts thereof and Difluprednate for the treatment of post operative ocular inflammation.